Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis

Yiming Zhao; Yongjian Wang; Hanyu Lou; Lizhen Shan

doi:10.18632/oncotarget.17515

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis

Yiming Zhao, Yongjian Wang _, Hanyu Lou and Lizhen Shan

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:81027-81039. https://doi.org/10.18632/oncotarget.17515

Metrics: PDF 1403 views | HTML 3061 views | ?

Abstract

Yiming Zhao1,*, Yongjian Wang1,*, Hanyu Lou1 and Lizhen Shan1

1 Department of Endocrinology and Metabolism, the Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang, China

* These authors have Contributed equally to this work

Correspondence to:

Yongjian Wang, email:

Keywords: alpha-glucosidase inhibitor, diabetes mellitus, cancer risk, meta-analysis, systematic review

Received: January 25, 2017 Accepted: April 17, 2017 Published: April 28, 2017

Abstract

Several studies have shown that anti-diabetic medications may modify the risk of cancer. We performed a systematic review and meta-analysis to evaluate the effect of alpha-glucosidase inhibitors (AGIs) on the risk of cancer in patients with diabetes mellitus. We conducted a systematic search of Medline, EMBASE, and Web of Science databases, up to September 30, 2016. Random-effects model was used to estimate the summary odds ratios (ORs) with 95% CI. Twenty-five studies (14 cohort, 7 case-control, and 4 randomized controlled trials) involving 1,285,433 patients with diabetes were included. Meta-analysis of observational studies showed that the use of AGIs was associated with a lower risk of developing cancer (OR = 0.86, 95% CI 0.78-0.96), especially gastrointestinal cancer (OR = 0.83, 95% CI 0.71-0.97). There was considerable heterogeneity across the studies introduced partly by the quality of included studies and adjustment for potential confounders. Meta-analysis of randomized controlled trials did not reveal any significant association between AGIs and cancer risk. Meta-analysis of observational studies indicated that AGIs may decrease the risk of cancer in individuals with diabetes.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17515

Publication Alerts

Meta-Analysis:

Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis

Abstract